Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company’s preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Pipeline Progress | Explore Kodiak's advancing clinical trials, including Phase 3 studies for wet AMD and diabetic retinopathy, with key data expected in 2025-2026. |
Financial Crossroads | Kodiak faces financial challenges with negative EPS projections, yet maintains a strong cash position and healthy current ratio of 8.42. |
Leadership Overhaul | Delve into the impact of Kodiak's new executive team, appointed in Q2 2024, on the company's strategic direction and operational efficiency. |
Market Valuation | Analyst price targets range from $3 to $4, reflecting cautious outlook. Average target of $3.25 suggests potential upside from current levels. |
Metrics to compare | KOD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipKODPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.0x | −3.6x | −0.5x | |
PEG Ratio | −0.06 | −0.01 | 0.00 | |
Price/Book | 1.7x | 1.6x | 2.6x | |
Price / LTM Sales | - | 18.2x | 3.0x | |
Upside (Analyst Target) | 4.4% | 207.4% | 52.7% | |
Fair Value Upside | Unlock | 2.0% | 7.6% | Unlock |